187 related articles for article (PubMed ID: 20569665)
1. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
5. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
McMillan GP; Konrad-Martin D; Dille MF
Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
[TBL] [Abstract][Full Text] [Related]
7. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
8. Fixed-Level Frequency Threshold Testing for Ototoxicity Monitoring.
Rieke CC; Clavier OH; Allen LV; Anderson AP; Brooks CA; Fellows AM; Brungart DS; Buckey JC
Ear Hear; 2017; 38(6):e369-e375. PubMed ID: 28362673
[TBL] [Abstract][Full Text] [Related]
9. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
10. A treatise on the thresholds of interoctave frequencies: 1500, 3000, and 6000 Hz.
Wilson RH; McArdle R
J Am Acad Audiol; 2014 Feb; 25(2):171-86. PubMed ID: 24828218
[TBL] [Abstract][Full Text] [Related]
11. Distortion product otoacoustic emission test performance when both 2f1-f2 and 2f2-f1 are used to predict auditory status.
Gorga MP; Nelson K; Davis T; Dorn PA; Neely ST
J Acoust Soc Am; 2000 Apr; 107(4):2128-35. PubMed ID: 10790038
[TBL] [Abstract][Full Text] [Related]
12. Early detection of ototoxicity using 1/6th-octave steps.
Fausti SA; Helt WJ; Phillips DS; Gordon JS; Bratt GW; Sugiura KM; Noffsinger D
J Am Acad Audiol; 2003 Oct; 14(8):444-50. PubMed ID: 14655957
[TBL] [Abstract][Full Text] [Related]
13. Audiometric threshold shift definitions: simulations and suggestions.
Dobie RA
Ear Hear; 2005 Feb; 26(1):62-77. PubMed ID: 15692305
[TBL] [Abstract][Full Text] [Related]
14. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma.
Bhagat SP; Bass JK; White ST; Qaddoumi I; Wilson MW; Wu J; Rodriguez-Galindo C
Int J Pediatr Otorhinolaryngol; 2010 Oct; 74(10):1156-63. PubMed ID: 20667604
[TBL] [Abstract][Full Text] [Related]
15. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
16. Distortion product otoacoustic emission test performance for a priori criteria and for multifrequency audiometric standards.
Gorga MP; Neely ST; Dorn PA
Ear Hear; 1999 Aug; 20(4):345-62. PubMed ID: 10466570
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
18. cis-platinum ototoxicity in children.
Pasic TR; Dobie RA
Laryngoscope; 1991 Sep; 101(9):985-91. PubMed ID: 1886448
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
[TBL] [Abstract][Full Text] [Related]
20. High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone.
Frank T
Ear Hear; 2001 Apr; 22(2):161-8. PubMed ID: 11324845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
